Management

Open and complete information on a routine basis is a guiding principle for the cooperation of MorphoSys’s Management Board and Supervisory Board. They work closely together and make decisions for the benefit of the company. Their stated objective is the sustainable increase in the company’s value.

Management Board

MorphoSys was co-founded in 1992 by today's CEO, Dr. Simon Moroney. Through the joint effort of the entire Management Board, the company has become one of the leading biopharmaceutical companies worldwide.

Dr. Simon E. Moroney

Chief Executive Officer

Biography

Dr. Simon E. Moroney

Chief Executive Officer

Year of Birth 1959
Nationality

German / New Zealand

Management Board Member of MorphoSys AG since 1999
End of appointment 2020

Dr. Moroney is one of the Company’s co-founders. Prior to that, Dr. Moroney held positions in the Department of Pharmacology, University of Cambridge, UK, as Assistant Professor in the Chemistry Department of the University of British Columbia, Vancouver, Canada, and as Associate in the Chemistry Department of the ETH in Zurich, Switzerland, where he also held a position as Lecturer. He was an Associate in the Harvard Medical School, Boston, USA, and an employee of ImmunoGen Inc., where he worked on the first generation of anti-cancer antibody conjugates.

Dr. Moroney studied chemistry in his native New Zealand, where he completed an MSc with 1st class honors and was a Commonwealth Scholar to the University of Oxford, where he was awarded a D.Phil. in Chemistry.

In 2002, Dr. Moroney received the German Cross of the Order of Merit by Dr. Johannes Rau, President of the Federal Republic of Germany, for his services to the biotechnology industry.

Dr. Moroney currently does not hold any other board memberships.

Jens Holstein

Chief Financial Officer

Biography

Jens Holstein

Chief Financial Officer

Year of Birth 1963
Nationality German
Management Board Member of MorphoSys AG since 2011
End of appointment 2020

Jens Holstein joined MorphoSys from Fresenius Kabi AG, where he most recently served as Regional CFO for the region EME (Europe/Middle East) and as Managing Director of Fresenius Kabi Deutschland GmbH. Over the last almost 16 years at Fresenius he had held a variety of financial and general management positions. From 2006 to 2010, he was Regional Chief Financial Officer of Fresenius Kabi Asia Pacific Ltd., based in Hong Kong. Prior to this appointment, Mr. Holstein was Managing Director of Fresenius ProServe GmbH and Chief Financial Officer and Labor Director of the company's subsidiary Wittgensteiner Kliniken AG. Earlier positions within Fresenius included General Manager of hospitalia care GmbH, Commercial Manager of the Projects & Service business unit of Fresenius AG and Commercial Manager of hospitalia international GmbH. Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry, with positions in Frankfurt and London.

Mr. Holstein holds a Diploma in Business Administration from University of Münster.

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

InflaRx N.V., Jena, Germany (publicly listed company) Member of the Board of Directors

Dr. Malte Peters

Chief Development Officer

Biography

Dr. Malte Peters

Chief Development Officer

Year of Birth 1962
Nationality German
Management Board Member of MorphoSys AG since 2017
End of appointment 2019

Dr. Peters joined MorphoSys from Sandoz International, Holzkirchen, Germany, where he was Global Head of Clinical Development of the Biopharmaceuticals Business Unit. Prior to this position, he served as Clinical Head and Site Head for Basel and East Hanover in the department of Oncology Translational Medicine at Novartis. Dr. Peters held teaching appointments in Internal Medicine and Biochemistry at the University of Mainz, Germany.

Dr. Peters received his MD degree from the Freie Universität Berlin, Germany, and was trained at the Universities of Padova, Italy and Bochum and Berlin, Germany. After scientific work at different universities he received his habilitation in Internal Medicine at the University of Mainz, Germany. Subsequently, he served as Research Scientist at the Amgen Research Institute in Toronto, Canada, as Director of Cancer Research at Merck KgaA in Darmstadt, Germany and as Medical Director at Micromet AG in Munich, Germany.

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Tango Therapeutics, Cambridge, MA, U.S. (not publicly listed company; group mandate) Member of the Board of Directors

Dr. Markus Enzelberger

Chief Scientific Officer

Biography

Dr. Markus Enzelberger

Chief Scientific Officer

Year of Birth 1969
Nationality Deutsch
Management Board Member of MorphoSys AG since 2017
End of appointment 2020

Dr. Enzelberger joined MorphoSys in 2002 and served in different leadership positions within R&D. Since 2012 he acted as Senior Vice President Discovery, Alliances and Technologies, taking responsibility for discovery programs for MorphoSys’s partners and MorphoSys’s proprietary pipeline as well as for the technology development. Dr. Enzelberger is co-inventor of the HuCAL Platinum and the Ylanthia libraries and worked on Guselkumab and many other programs within MorphoSys’s pipeline. His new areas of responsibility include discovery, technology development, protein sciences, manufacturing and alliance management.

Before joining MorphoSys, Dr. Enzelberger did his postdoc with Steven Quake at the California Institute of Technology on microfluidic biological assays, where he co-invented the key technologies of Fluidigm (South San Francisco, CA, USA).

Dr. Enzelberger studied Chemistry and was awarded a Doctor of Natural Sciences by the Technical University of Stuttgart, Germany. He performed his Diploma thesis together with Bayer and his PhD thesis with BASF on the use of enzymes in chemical processes.

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

SHS Gesellschaft für Beteiligungsmanagement mbH, Tuebingen, Germany
(not publicly listed company; group mandate)
Member of the Advisory Board

Related links

Supervisory Board

The Supervisory Board oversees and advises the Management Board. The Board consists of professionally qualified members with many years of experience in the biotechnology and pharmaceutical industries.

Dr. Marc Cluzel

Chairman

Biography and additional memberships

Dr. Marc Cluzel

Chairman

Year of birth 1955
Nationality French
Place of residence Montpellier, France
Initial Appointment 2012
End of Period 2021

Professional Development

Currently

Member of the Supervisory Board of MorphoSys AG as well as member of a comparable foreign supervisory board of a commercial enterprise (see below)

2011 – 2012

Executive Vice President of Product Development, HÙYÀ Bioscience International, LLC, San Diego, CA, USA

2009 - 2010

Executive Vice President of Research & Development, Sanofi-Aventis S.A., Paris, France

2007 – 2009

Senior Vice President of Science and Medical Affairs, Sanofi-Aventis S.A., Paris, France

2002 – 2011

Chairman and CEO, Sanofi-Aventis R&D France, Paris, France

1996 – 2001

Head of Project Direction, Sanofi R&D France, Paris, France

1993 – 1996

Project Director, Sanofi R&D France, Paris, France

1991 – 1993

Clinical Pharmacologist, Sanofi R&D France, Montpellier, France

Education

1983 – 1990 Ph.D. Biochemistry at University of Montpellier, France
1973 – 1985 M.D., Study of Medicine at University of Montpellier, France

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Moleac Pte. Ltd., Singapore* Member of the Board of Directors

*not publicly listed company; group mandate 

Dr. Frank Morich

Deputy Chairman

Biography and additional memberships

Dr. Frank Morich

Deputy Chairman

Year of birth 1953
Nationality German
Place of residence Berlin, Germany
Initial Appointment 2015
End of Period 2019

Professional Development

Currently

Self-employed business consultant in the life science and healthcare industries

2011 - 2014  Chief Commercial Officer and Member of the Board of Directors, Takeda Pharmaceutical Company Ltd., Tokyo, Japan, as well as CEO, Takeda Pharmaceutical International GmbH, Glattbrugg, Switzerland
2010 – 2011 Executive Vice President International Operations, Takeda Pharmaceutical International, Inc., Deerfield, IL, USA
2008 – 2010 CEO, NOXXON Pharma AG, Berlin, Germany
2005 – 2007 CEO and Member of the Board of Directors, Innogenetics N.V., Ghent, Belgium
2004 CEO and Chairman of the Executive Board, AM-Pharma B.V., Utrecht, The Netherlands
2003 – 2004 Independent consultant for the venture capital, life sciences and health care industries
2002 Chairman of the Board of Management and Chairman of the Executive Committee, Bayer HealthCare AG, Leverkusen, Germany
2000 – 2002 Member of the Board of Management, Bayer AG, Leverkusen, Germany
1993 – 2000 General Manager Consumer Care Division, Head of Global Product Development and Head of Research and Development, Bayer AG, Leverkusen, Germany
1991 – 1993 Director Clinical Research (CNS), Miles Inc., West Haven, CT, USA
1982 – 1991 Head of Institute of Biochemistry, Head of Institute of Pharmacology, Laboratory Head/Head of Cellular/In-Vitro Research, Institute of Pharmacology, Bayer AG, Wuppertal, Germany
1979 - 1980 Staff Physician, German Army, Marburg, Germany

Education

1992

“Managing for Global Success” Executive Development Program, Columbia University, NY, USA

1980 – 1982 Postdoctoral Fellow, Institute of Experimental Immunology, University of Marburg, Germany
1979 Dissertation & MD degree as physician and registered to practice medicine
1972 – 1979 Medical studies at the University of Marburg, Germany

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Cue Biopharma Inc., Cambridge, MA, USA (publicly listed company) Member of the Board of Directors

Krisja Vermeylen

Member

Biography and additional memberships

Krisja Vermeylen

Member

Year of birth 1962
Nationality Belgian
Place of residence Herentals, Belgium
Initial Appointment 2017
End of Period 2019

Professional Development

2015 - 10/2018 Senior Vice President Corporate People & Organisation, Novo Nordisk A/S, Bagsvaerd, Denmark
2013 – 2015

Corporate Vice President and General Manager (CVP), Novo Nordisk Pharma GmbH, Mainz, Germany

2008 – 2013

Vice President (France & BeLux), Novo Nordisk SA, Paris, France

2002 – 2013

Vice President Europe West (France, Belgium, Luxembourg, Netherlands), Novo Nordisk SA, Paris, France

1998 – 2002

General Manager (BeLux & Director GHT France), Novo Nordisk SA, Brussels, Belgium

1997 – 1998

Marketing & Sales Manager Diabetes/Women Health Care/Growth Hormone/Haemophilia, Novo Nordisk SA, Brussels, Belgium

1997

Marketing Manager Diabetes/Women Health Care/Growth Hormone, Novo Nordisk SA, Brussels, Belgium

1996 – 1997

Senior Product Manager Anaesthesia and Cardiovascular, Pharmacia & Upjohn, Brussels, Belgium

1995 Product & Sales Manager Low molecular weight heparin, Pharmacia, Brussels, Belgium
1994 – 1995 Product Manager Anaesthesia and Cardiovascular, Pharmacia, Brussels, Belgium
1993 – 1994 Product Manager Anaesthesia, Pharmacia, Brussels, Belgium
1991 – 1993 Medical Representative Hospital Division Parenteral Nutrition, Kabi Pharmacia, Brussels, Belgium
1986 – 1991 Pharmacist dispenser

Education

1985 – 1986 Doctoral student of bromatology at the University of Antwerp (UIA), Antwerp, Belgium
1980 –  1985 Pharmacist / Master in pharmaceutical sciences at the University of Antwerp (UIA, RUCA), Antwerp, Belgium

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Currently no memberships.

Wendy Johnson

Member

Biography and additional memberships

Wendy Johnson

Member

Year of birth 1952
Nationality US-American
Place of residence San Diego, CA, USA
Initial Appointment 2015
End of Period 2019

Professional Development

Currently

Managing Director, Gemini Advisors, San Diego, CA, USA;
Chief Operating Officer, AmpliPhi Biosciences Corp., Glen Allen, VA, USA

2007 – 2014 Founder, President and CEO, Aires Pharmaceuticals, Inc., San Diego,
CA, USA
2005 – 2014 Venture Partner, ProQuest Investments, San Diego, CA, USA
2001 – 2005 Senior Vice President Corporate Development, Salmedix, Inc., San Diego, CA, USA
2000 – 2001 Independent Consultant, San Diego, CA, USA
2000 – 1998

Vice President Business Development, Women First HealthCare, San Diego, CA, USA

1998 – 1994 Vice President Corporate Development & Operations, Selective Genetics, San Diego, CA, USA
1994 – 1990 Vice President Business Development & Regulatory Affairs, Cytel Corp., San Diego, CA, USA
1990 – 1988 Manager Business Development, Synbiotics Corp., San Diego, CA, USA
1988 – 1986 International Business Development & Regulatory Affairs Manager, Murex Corp., Cambridge, Great Britain
1986 – 1976 Assistant Director, US Food & Drug Administration, Center for Devices & Radiological Health, Rockville, MD, USA

Education

1986 – 1984

M.B.A., Loyola Marymount University, Los Angeles, CA, USA

1976 – 1974 M.S. Clinical Microbiology, Hahnemann University Hospital, Philadelphia, PA, USA
1974 – 1970 B.S. Microbiology, University of Maryland, College Park, MD, USA

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

AmpliPhi Biosciences Corp.* Member of the Board of Directors

 *not publicly listed company; group mandate

Dr. George Golumbeski

Member

Biography and additional memberships

Dr. George Golumbeski

Member

Year of birth 1957
Nationality US-American
Place of residence Far Hills, NJ, USA
Initial Appointment 2018
End of Period 2020

 

Professional Development

Since 2018

President, Grail Inc., Menlo Park, CA, USA (as of August 1, 2018)

Since 2018

Self-employed business consultant in the life science and healthcare industries (as of April 17, 2018)

2017 – 2018

Executive Vice President & Executive Advisor for Innovation, Celgene Corporation, Summit, NJ, USA (until April 16, 2018)

2009 – 2017

Executive Vice President, Business Development, Celgene Corporation, Summit, NJ, USA

2008 – 2009

Chief Executive Officer, Nabriva Therapeutics AG, Vienna, Austria

2002 – 2008

Vice President, Business Development, Lincensing & Strategy, Novartis Oncology, Florham Park, NJ, USA

2001 – 2002

Vice President, R&D Business Development, Elan Biopharmaceuticals, San Diego, CA, USA

2000 – 2001

Senior Director, Licensing, EMD Pharmaceuticals, Durham, NC, USA

1997 – 2000

Vice President / Director, Corporate Development, Schwarz Pharma, Mequon, WI, USA

1996 – 1997

Director, Business Development, Pierce Chemical Company, Rockford, IL, USA

1991 – 1995

Technology Acquisition Manager / Group Leader, Research & Development / Group Leader, Diagnostics Research & Development, Promega Corporation, Madison, WI, USA

 

Education

1985 Ph.D., Genetics, University of Wisconsin-Madison, Madison, WI, USA
1986 – 1991 Postdoctoral Research, Molecular biology, University of Colorado Boulder, Boulder, CO, USA
1997 B.A., Biology, University of Virginia, Charlottesville, VA, USA

 

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

BioSight Ltd., Lod, Israel* Chairman of the Board of Directors
BlackThorn Therapeutics, Inc., San Francisco, CA, USA* Member of the Board of Directors
Carrick Therapeutics Ltd., Dublin, Ireland* Chairman of the Board of Directors
Enanta Pharmaceuticals, Inc.,
Watertown, MA, USA (publicly listed company)
Member of the Board of Directors
Grail Inc., Menlo Park, CA, USA* Member of the Board of Directors
KSQ Therapeutics, Inc., Cambridge, MA, USA* Member of the Board of Directors
PMV Pharmaceuticals, Inc., Cranberry, NJ, USA* Member of the Board of Directors
Shattuck Labs, Inc., Austin, TX, USA* Member of the Board of Directors
Tizona Therapeutics, Inc., San Francisco, CA, USA* Member of the Board of Directors
Acceleron Pharma Inc.,
Cambridge, MA, USA (publicly listed company)
Member of the Board of Directors

* not publicly listed company; group mandate

Michael Brosnan

Member

Biography and additional memberships

Michael Brosnan

Member

Year of birth 1955
Nationality US-amerikanisch
Place of residence Westford, MA, USA
Initial Appointment 2018
End of Period 2020

Professional development

Since 2010 Chief Financial Officer, Fresenius Medical Care Management AG, Bad Homburg v.d.H, Germany
2003 – 2009 Executive Vice President and Chief Financial Officer, Fresenius Medical Care North America, Waltham, MA, USA
1999 – 2003 Senior Vice President of Finance, Fresenius Medical Care North America, Waltham, MA, USA
1998 Vice President Finance and Administration, Spectra Renal Management, Waltham, MA, USA
1997 Vice President of Financial Operations, High Voltage Engineering Corporation, Wakefield, MA, USA
1994 – 1996 Senior Controller, Commercial Imaging Group, Polaroid Corporation, Cambridge, MA, USA
1978 – 1993 KPMG, Boston, MA, USA, (1988 – 1993 Audit Partner)

Education

1978 BSc, Business Administration, Accounting, Northeastern University, Boston, MA, USA

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Fresenius Medical Care Holdings, Inc., U.S.*, Waltham, MA, USA Member of the Board of Directors
Vifor Fresenius Medical Care Renal Pharma Ltd., CH* Glattbrugg, Switzerland Member of the Board of Administration

 *not publicly listed company; group mandate

Composition of the Supervisory Board since Termination of the 2018 Annual Gerneral Meeting

  Initial
Appointment
End of
Period
Audit
Committee
Remuneration and Nomination
Committee
Science
and Technology
Committee
Dr. Marc Cluzel 2012 2021  
 
Dr. Frank Morich 2015 2020  
Krisja Vermeylen 2017 2019
 
Wendy Johnson 2015 2020
 
Dr. George Golumbeski 2018 2020  
Michael Brosnan
2018 2020
   

Independent Financial Expert     Chairperson     Member

 

Composition of the Supervisory Board until Termination of the 2018 Annual Gerneral Meeting

  Initial
Appointment
End of
Period
Audit
Committee
Remuneration and Nomination
Committee
Science
and Technology
Committee
Dr. Gerald Möller 1999 2018  
 
Dr. Marc Cluzel 2012 2018  
Krisja Vermeylen 2017 2019
 
Wendy Johnson 2015 2020
 
Klaus Kühn
2015 2020
   
Dr. Frank Morich 2015 2020    

Independent Financial Expert     Chairperson     Member